CA Patent

CA2751834C — Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof

Assigned to Boehringer Ingelheim International GmbH · Expires 2018-07-24 · 8y expired

What this patent protects

The invention relates to a pharmaceutical combination comprising: (a) the SGLT2 inhibitor 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, (b) the DPPIV inhibitor linagliptin or a pharmaceutically acceptable salt thereof, and (c) an anti…

USPTO Abstract

The invention relates to a pharmaceutical combination comprising: (a) the SGLT2 inhibitor 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, (b) the DPPIV inhibitor linagliptin or a pharmaceutically acceptable salt thereof, and (c) an antidiabetic agent, wherein the an antidiabetic agent is metformin or a pharmaceutically acceptable salt thereof, for combined or simultaneous or sequential use of the SGLT2 inhibitor, the DPP IV inhibitor and the antidiabetic agent. The combination may be used for improving glycemic control.

Drugs covered by this patent

Patent Metadata

Patent number
CA2751834C
Jurisdiction
CA
Classification
—
Expires
2018-07-24
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.